Citius pharmaceuticals announces key management realignment to support commercialization of two late-stage product candidates

Leonard mazur named chairman of the board of directors and ceo of citius citius co-founder, myron holubiak to transition from president & ceo to executive vice chairman of the board of directors to build commercial capabilities, effective may 1, 2022 jaime bartushak, chief financial officer, to assume additional responsibilities as chief business officer commercial capabilities strengthened with addition of michael mcguire as vp, program leader for anti-infectives cranford, n.j. , april 13, 2022 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that the board of directors has approved key management changes to strengthen the company's commercial capabilities as its two late phase 3 programs for i/ontak (e7777) and mino-lok® near completion.
CTXR Ratings Summary
CTXR Quant Ranking